GLPwatch
Papers (12034)
Page 168 of 201, ranked by citation count.
- Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX-SEMA 2.4 mg, an Italian real-world study.
- Cardiovascular benefits of obesity therapies: an overview of obesity medicines and metabolic bariatric surgery.
- Association Between GLP-1 Receptor Agonists and the Risk of Colon Cancer in Adults With Type 2 Diabetes or Obesity: A Systematic Review and Network Meta-Analysis.
- Weight Loss-Independent Mechanisms of Kidney Protection With Glucagon-Like Peptide 1 Receptor Agonists and Implications for Clinical Practice.
- Liraglutide attenuates aluminum chloride-induced Alzheimer's disease in rats by modulating the oxLDL/LPA/LPAR1 pathway.
- Impact of GLP-1 RA plus progestin therapy on fertility-sparing management of endometrial intraepithelial neoplasia and endometrial cancer.
- Assessing the Safety of Semaglutide and Tirzepatide in Black and Asian Populations: A Narrative Review.
- Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT-1 and SURMOUNT-2 Trials.
- Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis.
- Correction to Dulaglutide Alleviates LPS-Induced Injury in Cardiomyocytes.
- Dose-response analysis of tirzepatide and acute pancreatitis: An international systematic review and quantitative meta-analysis of randomised trials.
- Targeting Inflammation and Fibrosis in Lipedema: The Potential Role of Glucagon-like Peptide-1 Receptor Agonist Therapies.
- Cost effectiveness analysis of six non insulin agents for type 2 diabetes in Iran using a patient level simulation with UKPDS OM2.
- How Low Could Semaglutide Prices Fall? An Analysis of Production Cost and Implications for Global Access.
- The Effect of Semaglutide With Lifestyle Intervention on the Physical Health of Patients Treated With Antipsychotic Drugs in a Secure Mental Health Setting: Protocol for an Uncontrolled Pretest-Posttest Pilot Mixed Methods Study.
- A randomized controlled trial protocol of the cardiovascular safety and efficacy of liraglutide in the treatment of type 2 diabetes.
- Clinical evidence of semaglutide for metabolic dysfunction-associated steatotic liver disease (MASLD): An updated meta-analysis.
- Metabolic inflammation at the adipose-brain axis.
- Effect of Tirzepatide Treatment on Hepatic Biomarkers in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes Mellitus.
- Tirzepatide for type 2 diabetes.
- Tirzepatide in Metabolically Dysfunctional-Associated Steatohepatitis (MASH): A Bibliometric and Evidence-Based Review.
- Effect of Tirzepatide on arrhythmic, major cardiovascular, and neurological outcomes in patients with type 2 diabetes: A systematic review and meta-analysis.
- Safety and Efficacy of Switching Patients With Type 2 Diabetes From Glucagon-Like Peptide-1 Receptor Agonists to Tirzepatide: A Case Series.
- Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine.
- Agent-specific, histopathology-stratified hematologic malignancy risk among dpp-4 inhibitors, glp-1 receptor agonists, and SGLT2 inhibitors: a network meta-analysis of 270,471 participants.
- [Basal insulin degludec - liraglutide fixed ratio combination (Xultophy®)].
- A Pharmacovigilance Analysis of Ocular Adverse Events Associated with GLP-1 Receptor Agonists.
- [Efficacy and safety of IdegLira for the intensification of type 2 diabetes treatment].
- Exenatide treatment causes suppression of serum fasting ghrelin levels in patients with type 2 diabetes mellitus.
- A Clinical Comprehensive Evaluation of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes Management.
- Relative Efficacy of Next-Generation Incretin Therapies for Cardio-Renal Protection in Type 2 Diabetes: Evidence From a Network Meta-Analysis.
- Oral Delivery of Semaglutide and Tirzepatide Using Milk-Derived Small Extracellular Vesicles.
- Energy-Metabolism-Enhancing Probiotics Enhance the Therapeutic Response to a Glucagon-like Peptide-1 Receptor Agonist.
- Comparison of Exendin-4 and Its Single Amino Acid Substitutions as Parent Peptides for GLP-1 Receptor Imaging Probes.
- The nuclear option for insulinomas.
- RGB Trichromatic Whiteness Assessment of Bio Analytical Chromatographic Tool Using Fluorescence for Quantitation of Semaglutide: Application to Pharmaceutical Preparations and Spiked Plasma.
- Gliptins, exenatide, liraglutide: "intestinal obstruction".
- GLP-1 Receptors Are Enriched in the Lymphatic Endothelium and Their Pharmacological Activation With Semaglutide Improves the Pumping Capacity of Lymphatic Vessels.
- Influence of Combination Therapy with Dulaglutide or Liraglutide and SGLT2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Post-hoc Analysis of the RECAP Study.
- Semaglutide Overdose in a Diabetic Patient: Suicidal Behavior and Multiorgan Failure.
- Dapagliflozin restores odour-induced functional integration of primary olfactory cortex circuit but not olfactory-related regional brain activation in patients with type 2 diabetes: A 16-week randomised comparative study.
- Real-World Weight-Loss Outcomes in Weight-Reduced Patients Treated With Tirzepatide.
- In brief: Semaglutide (Wegovy) for weight loss in children.
- Association learning is impaired in insulin resistance and restored by liraglutide.
- Characterization of Interchanging Incretin Analogs in Clinical Practice: A Descriptive Report.
- Is pharmacotherapy enough for urgent weight loss in severely obese patients?
- Glucagon-like peptide-1 receptor agonists in patients with heart failure with reduced ejection fraction.
- Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials.
- Association of Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review.
- Comparative Analysis of Efficacy and Safety of the Glucagon-Like-Peptide-1 Receptor Agonists Tirzepatide and Semaglutide in Solid-Organ Transplant Recipients.
- Recombination and functional studies of a dual-action peptide for diabetes.
- Impact of Time of Injection on the Efficacy and Safety of iGlarLixi Versus IDegAsp in Chinese People With Type 2 Diabetes: Exploratory Analysis of the Soli-D Study.
- Neuroprotective effects of semaglutide targeting the left temporal lobe in adults with overweight or obesity: A 24-week multimodal neuroimaging study.
- Weight-Reduction and Safety Profile of Once-Weekly Non-Comparable Biotherapeutic Subcutaneous Semaglutide Among People With Obesity: A Real-World Retrospective Study.
- Influence of Hydrophobic Ion Pairing on Formulation Performance of Liraglutide in PLGA Microspheres.
- [Obesity treatment with liraglutide in a patient with Prader-Willi syndrome: a case report].
- Predictive factors associated with three years of response to HbA1c goals with exenatide QW or insulin glargine: Post-hoc analysis of the DURATION-3 study.
- Glucagon-like peptide-1 and atrial fibrillation incidence: Associations independent of weight loss.
- Development of a risk prediction model for gastrointestinal adverse events associated with semaglutide administration in patients with type 2 diabetes mellitus.
- Cardiovascular efficacy of tirzepatide: what real-world evidence promises.